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Oral lesions have different etiologies, although many of them can be largely attributed 
to environmental exposures. Tobacco use, chewing areca nuts, and alcohol 
consumption are well-established risk factors for various lesions of the oral cavity. 
Infectious agents also play an important role in the etiology of oral lesions. Among 
them, human papilloma viruses (HPV) seem to be associated with a subset of oral 
benign proliferative and malignant lesions, and the head and neck carcinoma, notably 
carcinoma of the oropharynx, tonsils and tongue (Mravak-Stipetic et al., 2013). 
HPV is a small, epitheliotropic, non-envelopedDNA virus. The HPV genome consists 
of 7200 to8000 base pairs of closed-circular double-strandedDNA, containing up to 
10 open reading frames (ZurHausen, 1996). HPV infection is the mostcommon of all 
sexually transmitted diseases. Oral HPVinfection can be acquired by oral-genital 
contact, by mouth to mouth contact, or possibly by autoinoculation and ininfants by 
mother-to-child transmission (Brentjenset al., 2002). 
Human papilloma virus (HPV) causes a wide spectrum of diseases affecting the 
cutaneous and mucosal areas of the body, ranging from benign common warts to 
invasive carcinoma. HPV infections have been reported in a number of body sites, 
including the anogenital tract, urethra, skin, larynx, tracheobronchial mucosa, nasal 
cavity, paranasal sinus, and oral cavity. Oral HPV infection may be associated with 
different diseases of the oral cavity (Kumarasamy et al., 2011). 
Till date, more than 200 different HPV types,ranging from HPV-1 to HPV-210 have 
been officiallyrecognized by the International HPV Reference Center. Four of the 
previously recognized HPV types (HPV-46,HPV-55, HPV-64 and HPV-79) were 
recently re-classified as subtypes (Ostrebenck et al., 2015). HPV types infecting the 
mucosa are further classified into high and low-risk groups based on the type 
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oflesions they cause. Low-risk type HPVs like HPV-6 and HPV-11 cause benign 
warts. High-risk HPVs, such as HPV-16 and HPV-18, cause premalignant squamous 
intraepithelial neoplasias that can progress to cancer (Doorbar et al., 2012).  
Generally, oral epithelium undergoes a sequence of histopathological changes like 
hyperplasia and dysplasia before the development of invasive carcinoma. According 
to World Health Organization (WHO) 2005, hyperplasia is defined as increased 
cell numbers in the spinous layer and/or in the basal and suprabasal cell layers. The 
architecture shows regular stratification without cellular atypia. Detection of HPV in 
oral epithelial hyperplastic conditions would be essential to recognize the factors that 
determine its capability to induce cellular proliferations. 
The specific role of human papillomaviruses (HPV) in the development of 
premalignant lesions and oral squamous cell carcinoma (OSCC) continues to be a 
much-debated topic (Syrjanen, 2000; Adelstein et al., 2009).Recently, the common 
term “oral potentially malignant disorders” has been suggested to include both oral 
precancerous lesions (e.g. leukoplakia, erythroplakia, oral proliferative verrucous 
leukoplakia) and oral precancerous conditions (e.g. lichen planus, submucous 
fibrosis). All oral mucosal lesions that carry a risk of malignant transformation are 
included under this term (Warnakulasuriya et al., 2007;Van der Waal, 2009). 
Leukoplakia is the most common potentially malignant lesion in the oral cavity. 
Tobacco and areca nut use, either alone or in combination,are the most common risk 
factors for oral leukoplakia, although some are idiopathic. Leukoplakia may 
unpredictably regress, remain stable or progress to carcinoma. There is a greater risk 
of carcinomatous transformation of idiopathic leukoplakia, non-homogenous 
leukoplakia, leukoplakia affecting the high-risk sites and leukoplakia in which the 
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keratinocytes carry cytogenic alterations associated with carcinomatous 
transformation (Feller, 2012). Although there appears to be some link between HPV 
and oral leukoplakia, there is little evidence to support a causal relationship either 
between HPV infection and oral leukoplakia or between HPV infected keratinocytes 
and their malignant transformation. 
Oral lichen planus (OLP) is a chronic autoimmune disorder of unknown etiology in 
which predominantly T-lymphocytes accumulate beneath the epithelium and increase 
the rate of differentiation of stratified squamous epithelium, resulting in either 
epithelial thickening or atrophy with or without ulceration (Epstein et al.,2003). Oral 
submucous fibrosis (OSMF) is a chronic potentially malignant disorder characterized 
by fibrosis of the lining mucosa of the upper digestive tract involving the oral cavity 
and oropharynx and the upper third of the esophagus. Malignant transformation 
ratesas high as 7.6% in OSMF have been reported from the Indian subcontinent over a 
17 years period. Giovannelli et al., 2002 had detected the presence of HPV in OLP 
and OSMF, but studies evaluating the strength of this association are minimal. Till 
date, there is a paucity of information on the potential role of HPV in potentially 
malignant lesions. 
Globally, oral cancer is a major public health problem accounting for approximately 
3% of all cancers (Bixofis et al., 2014; Hubbers and Akgul, 2015; Komolmalai et 
al., 2015).In India, oral cancer constitutes around 9.8% of total cancer cases and ranks 
first among all the cancer cases in males and is the third most common among 
females (Rajendran et al., 2009).  Cancer is a disease of cells that escape the control 
mechanisms of orderly cell growth and acquire the ability to proliferate, invade 
normal tissues and metastasize (Koss et al., 2006). Squamous cell carcinoma accounts 
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for more than 90% of malignant tumors of the oral cavity (Johnson et al., 
2011).Almost all squamous cell carcinomas in the oral cavity are often preceded by 
pre-existing oral potentially malignant disorders (Warnakulasuriya, 2007).It is well 
accepted that both genetic and environmental factors play a pivotal role in OSCC 
carcinogenesis (Pannone et al., 2011). Well-known major environmental risk factors 
for OSCC include tobacco use in various forms, heavy alcohol consumption, areca 
nut/betel quid chewing (Komolmalai et al., 2015; Sritipphoet al., 2015).This is in 
contrast to the recent controversial Johns Hopkins study claiming that cancer is a bad 
luck happening due to random mutations arising during DNA replication in normal, 
non-cancerous stem cells in about two third of the cases, not either related to heredity 
or ecological factors(Tomasattiet al., 2015).However, approximately 15-20% of 
patients with OSCC in the Western population are not linked with those conventional 
risks, and lately, high-risk humanpapillomaviruses (HR-HPV) have been found to 
have greater association in such patients (Vargas-Ferreira et al., 2012).  
Bosh et al. in 2002 reported that approximately 15% of all malignancies worldwide 
appear to be connected with viral infections, and several human DNA viruses are now 
accepted as causative factors. Viruses that have been implicated in oral neoplasias 
include Epstein-Barr virus, human herpes virus 8, human cytomegalovirus, and 
particularly, human papillomaviruses (Atula et al., 1998). 
HPVs are characterized by epitheliotropism. Target cellsare the cells found in germ 
layers of the skin and mucousmembranes(Morshed, 2014).HPV associated 
carcinogenesis is mediated by expression of the viral E6and E7 oncoprotein, which 
cause deregulation of the cell cycle by inactivating p53 and pRb respectively(Bouda, 
2000). This results in cell proliferation and malignant transformation (Weist, 2002). 
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Ubiquitination mediated by E6 and degradation ofp53 manifest as deregulated cellular 
proliferation and progressive telomerase erosion. This erosion is markedly inhibited 
through the ability of HPV E6 to induce expression of telomerase reverse 
transcriptase and to interact with the telomerase complex, resulting in activation of 
telomerase and thereby resulting in cellular immortalization(Liu et al., 2009). E7 
targets other cellular proteins that are relevant to cell-cycle progression. E7 is known 
to interact with p21 and target it for ubiquitin-proteosomal degradation, resulting in 
initiation of the stationary(S) phase of the cell cycle (Rautava and Syrjänen, 2012). 
E6 and E7 are known to activate the Wntsignaling pathway, resulting in protection of 
β-catenin fromthe phosphorylation and proteosomal degradation of GSK-3β, in turn 
bringing about the transcription of cyclin D1, which initiates the gap-1(G1) phase of 
the cell cycle (Rampiaset al., 2010).As E6 and E7 oncoprotein of high-risk HPV 
genotypes have the capacity to mediate malignant transformation of infected 
keratinocytes by inactivating cellular p53 and pRbtumor suppressor pathways, HPV 
may play either an oncogenic or a co-oncogenic role in some HPV related 
precancerous and cancerous epithelial neoplasms (Vidal, 2008).  
Hence this study was designed to evaluate the presence of HPV in oral epithelial 
hyperplasia, dysplasia and oral squamous cell carcinoma using E6 oncoprotein of 
HPV 16/18 immunohistochemical marker that might help in better understanding of 
the role played by virus in oncogenic process from its evolution stage. Investigation 
on the role of HPV could be rewarding in planning long term strategies for 
prevention, diagnosis and possible treatment option of these (leukoplakia, oral 
submucous fibrosis, lichen planus and oral squamous cell carcinoma) conditions. 
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AIM OF THE STUDY: 
 To assess the immunoexpression of E6 oncoprotein of human papilloma virus 
16/18 in oral epithelial hyperplasia, oral epithelial dysplasia & oral squamous 
cell carcinoma 
 
OBJECTIVES OF THE STUDY: 
 To evaluate the expression of E6 oncoprotein of human papilloma virus 16/18 
in oral epithelial hyperplasia, oral epithelial dysplasia & oral squamous cell 
carcinoma 
 To compare the expression of E6 oncoprotein of human papilloma virus 16/18 
among the different study groups 
 To evaluate the number of koilocytes in H and E stained sections of oral 
epithelial hyperplasia, oral epithelial dysplasia & oral squamous cell 
carcinoma 
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Papilloma viruses are small, non-enveloped, epitheliotropic, double-stranded DNA 
viruses that infect mucosal and cutaneous epithelia in a wide variety of higher 
vertebrates in a species-specific manner and induce cellular proliferation. More than 
200 types of human papilloma viruses (HPVs) have been identified and 
approximately half of them infect the genital tract. Many types of HPV have been 
found in cervical cancers, while others are found rarely or not at all in large series of 
cancers, which gives rise to the nomenclature of ‘high-’ and ‘low-risk’ HPVs. These 
high-risk types are associated with other anogenital and oropharyngeal cancers 
(ZurHausen et al., 1996). 
HPV genome organisation 
All papilloma viruses share a common genetic structure that includes a double-
stranded circular DNA genome containing approximately 7,900 base pairs associated 
with histones (Favre et al.,1975). It has an icosahedral capsid composed of 72 
capsomeres.Each capsomere is a pentamer of the major capsid protein. Each virion 
capsid contains several copies of the minor capsid protein which is of about 12 per 
virion. The genome of HPV is functionally divided in to 3 regions 
  
Genome of HPV 
Non coding 
upstream 
regulatory region 
Early region 
Late region 
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Non-coding upstream regulatory region: 
The non-coding control region does not have any protein-coding function itself but 
contains both the origin of replication as well as binding sites for transcription factors, 
thus regulating the transcription of the different genes. 
Early region: 
It includes the genes E1, E2, E3, E4, E5, E6, E7 and E8. This region is involved in 
viral replication and oncogenesis. Expression of the early gene products determines 
whether an HPV infection is active or latent or leads to malignant transformation. It 
composes more than 50% of the viral genome. 
Late region  
The late region lies downstream of the early region and encodes two late proteins (L1 
and L2), which together make up the viral capsid. 
 
 
  
Figure 1: HPV genome showing the 
arrangement of early (E) and late genes (L) 
and the upstream regulatory region (URR). 
In yellow and orange: late structural 
proteins; in blue, green, red and purple: 
earlyproteins; in red and purple: viral 
oncogenes. 
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Viral proteins 
E1 and E2: 
The E1 protein is generally expressed at a low level and is only active in an efficient 
way upon interaction with E2. These two proteins together are considered to be the 
most important ones during early infection. They join together with cellular DNA and 
form a complex, which recruits other proteins necessary for replication (Doorbar, 
2006). 
E2, in combination with E1, has a regulatory function. E1 encodes a protein with 
ATPase and helicase activities and is essential for viral replication. E2 gene encodes a 
DNA-binding protein that binds to target sequences around the viral origin and 
recruits the E1 helicase which in turn is involved in replicating the viral genome by 
recruiting host replication proteins. In addition to its role in viral DNA replication, the 
E2 protein functions as a transcriptional repressor for the expression of E6 and E7 
oncoprotein. 
E4  
This protein is mostly synthesized in the late phase of viral replication and associates 
with the cytoskeleton in differentiating keratinocytes and is then assumed to take part 
in the collapse of the cytokeratin filament. As keratinocytes differentiate, they 
develop aninsoluble matrix of covalently linked proteins which protect it from 
mechanical injury. This protein matrix is referred to as the cornified envelope. 
Cytokeratin collapse induced by E4 is suggested to affect the integrity of the cornified 
envelope of the host cell, aiding the newly formed virions(Bryanet al., 2000). 
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Also,E4 has the ability to relocate cyclin B/Cdk2 complexes from the nucleus to the 
cytoplasm, thereby inducing cell-cycle arrest in the G2-phase (Davy et al., 2006). 
E5  
E5 is a transmembrane protein, localized mainly to the endoplasmic reticulum (ER) 
and Golgi apparatus. E5 binds vacuolar proton-ATPase on cellular endosomes, ending 
up in disrupted endosomal pH. This change in pH blocks internalization of the 
epidermal growth factor receptor (EGFR). In turn, the blocking of internalization 
leads to EGFR being recycled back to the cell surface, increasing receptor activity and 
cellular proliferation. However, E5 is considered to be an oncoprotein with low 
transforming capacity (Moody et al., 2010) 
E6  
One of the main functions of high-risk HPV E6 is deregulation of the tumor 
suppressor p53. This is achieved when E6 associated protein (E6AP) forms a complex 
with E6 and binds to p53, leading to its ubiquitination and degradation (Schefner et 
al., 1990). 
E6 of high risk and low risk HPVs differ from each other. Although they both bind to 
p53, only binding by HR-HPV E6 results in p53 degradation. The reason for this is 
still unclear, but it has been suggested that HR-HPV E6 can bind at two locations 
whereas LR-HPV E6 only binds to one, thereby only retaining the protein in the 
cytoplasm. Nevertheless, both HR- and LR-HPV E6 can bind directly to the p53 gene 
and block its transcription. Another way in which E6 can affect p53 is by preventing 
its acetylation and hence blocks stabilization of the p53 protein. This is achieved by 
binding of E6 to histone acetyl transferases p300 and CBP (CREB-binding protein), 
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which would normally acetylate p53 and hence activate it. E6 also binds to proteins 
containing a PDZ (P- post synaptic density protein; D: D1g protein; Z: Zona 
occludens protein) -domain, inducing degradation of the same, thereby contributing to 
deregulation of cellular adhesion, proliferation and chromosomal integrity. E6 can 
also induce telomerase activity, affect interferon signaling by blocking of interferon 
regulatory factor 3 (IRF3) and mediate degradation of pro-apoptotic proteins (such as 
BAK, BAX), all contributing to further oncogenesis. 
E7  
E7, more specifically HR-HPV E7, is best known for its capacity to bind and 
destabilize the tumor suppressor pRb, p107 and p130. All three are related and 
regulated by E2F-family members. Binding of E7 to pRb disrupts formation of the 
pRb-E2F complex, and this in turn releases E2F. This release will contribute to other 
cellular effects such as G1/S-checkpoint deregulation and cyclin A and E activation. 
Binding of HR HPV E6 to p53 and LR-HPV E6 to p53 differ from each other. 
Similarly, difference in the pRb binding domain has been observed between LR- and 
HR-HPV E7, with a greater binding affinity to pRb for the latter (Klingelhutz et al., 
2012). In addition, E7 has the ability to block the effects CDK-inhibitors (cyclin 
dependent kinase-inhibitors) p21 and p27 and induce chromosomal instability (Zur 
Hausen, 2002). E7 also exhibits an immune modulating capacity. This capacity is 
initiated as E7 binds to the interferon regulatory factor 9 (IRF-9), which is involved in 
the signaling pathway of interferon-α (IFN- α), and by blocking the nuclear 
translocation of IRF-9. Hence indirectly, it blocks the antiviral function of IFN- α 
(Antonsson et al., 2006). Furthermore, it has been proposed that E7 may block 
activation of the IFN-β promoter by inhibiting IRF-1 signaling. This might be exerted 
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as E7 can act directly on IFN-γ, suppressing its activation of IRF-1 and hence 
negatively affect MHC class I presentation and IFN-β activation (Zhou et al., 2013). 
E3 and E8  
E3 and E8 gene have been observed only in a few papilloma viruses and has not been 
proven to encode any protein or serve any function 
Life cycle of HPV 
HPV life cycle is closely linked to the differentiation program of infected epithelial 
cells, more specifically the keratinocytes. The receptors involved are not fully 
identified, but some data reveal a role for α6 integrin and heparin sulfate(IARC 
Monographs on the Evaluation of Carcinogenic Risks to Humans. 2007). ά6β4 
acts as promising candidate for human papilloma virus (HPV) infection (Evander et 
al., 1997). 
Binding, entry and uncoating 
Most of the studies prove that different types of HPVs entered cells in distinct 
pathways including clathrin-mediated endocytosis, caveolar endocytosis, clathrin and 
caveolae-independent endocytosis (Letian and Tianyu, 2010). HPV infection needs 
to access the cells which are present in the basal layers of stratified epithelium and for 
that some HPV types require micro traumas to occur in stratified epithelium. Such 
breaks may not be readily apparent, and these conditions occur where the skin is 
exposed to water or is abraded. To maintain the HPV infection, the virus has to infect 
an epithelial stem cell (Doorbar et al., 2005; IARC, 2012; Muñoz et al., 2006; 
Stubenrauch and Laimins, 1999). 
 
REVIEW OF LITERATURE 
 
13 
 
Establishment and maintenance of the non-productive infectious state: 
Following HPV infection and uncoating, the HPV replication cycle within the 
epithelium can be divided into two parts nonproductive and productive. Initially, 
HPV genomic DNA is transported into the nucleus and maintained at a low copy 
number in the basal cells (50 - 100 copies/cell) in the basal cell layer. The ability of 
HPVs to establish their genome in basal cells relies upon the E1, E2, E6 and in some 
cases E7. The viral proteins E1 and E2 are essential for this basal DNA replication 
(Hoenil and Jae, 2005; IARC, 2012). This is consequently referred to as the non-
productive stage of infection. This requires that the viral genome be maintained over 
multiple cell divisions. 
Productive stage: 
For the production of infectious virions, human papilloma viruses amplify their viral 
genomes to ~1000 copy numbers per cell and package them into infectious particles 
(Hoenil and Jae, 2005). In HPV-positive human keratinocytes and cervical epithelial 
cells, after producing sufficient number of HPV progenies in the basal cells, basal 
cells are pushed to the suprabasal compartment where they fail to withdraw from the 
cell cycle and continue to support DNA synthesis (Doorbar, 2005; IARC, 2007). For 
high risk HPV types such as HPV16, this occurs in the mid or upper epithelial layers 
following an increase in activity of the late promoter. It is proven that E7 up-
regulation leads to increased expression of E1, E2, E4 and E5 proteins which are 
involved in viral DNA replication without directly affecting expression of the E6 and 
E7 proteins.  
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Genome amplification: 
Amplification of viral genomes begins in a subset of cells in the proliferative 
compartment and requires expression of all viral early gene products including E4 and 
E5 (Doorbar,2005). 
Virus synthesis and assembly: 
 The amplified HPV genome encodes two structural proteins L1 and L2. L2 is a minor 
coat protein and is produced in a subset of the cells that express E4. The major capsid 
protein (L1) is expressed after L2 allowing the assembly of infectious particles in the 
upper layers of the epithelium (Doorbar,2005; Ozbun and Meyers, 1998). The 
critical molecules involved in the process of virus replication are the viral proteins E6 
and E7 (Doorbar, 2005).  
 
 
  
Figure 2: Human Papillomavirus Life Cycle: A: Early gene expression E1, E2, 
E6 and E7; B: Viral genome amplification; C: Virion assembly and release  
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Virus release: 
For HPV particles to release into the environment, the HPV has to escape from the 
infected skin cell and survive extra-cellularly prior to re-infection. Papilloma viruses 
are non-lytic and are not released until the infected cells reach the epithelial 
surface.Extra-cellular survival of the Papilloma viruses may be enhanced when they 
shed from the epithelial surface within a cornified squame. This may compromise the 
immune detection of the virus and thus limit the presentation of viral epitopes to the 
immune system in the lower epithelial layers (Doorbar, 2005; Muñoz et al., 2006).  
Viral transmission: 
HPVs are prevalent worldwide and infection with cutaneous HPV is ubiquitous. The 
common mode of transmission and acquisition of HPV is by horizontal transmission 
consequent to sexual activity. According to epidemiologic studies vaginal and anal 
sexual intercourse is the primary route for anogenital HPV infection. However, 
penetrative sexual intercourse is not a requirement for HPV transmission(Wright, 
2009). There is a strong relationship between the number of both lifetime and recent 
sexual partners and the prevalence of HPV in women (Shukla et al., 2009). Open 
mouth-to-mouth kissing is also a means of nonsexual transmission. Occasionally, 
HPV may be transmitted through modes other than sexual activity. These routes 
include vertical transmission (mother to child). HPV can be transmitted to the mouth 
and upper airway of a newborn from an infected mother during birth, which can result 
in recurrent respiratory papillomatosis and severe breathing difficulties in infants. 
Nosocomial transmission of HPV present in fumes caused by laser ablation of lesions 
is believed to be possible. Transmission of HPV is caused by direct contact of skin or 
mucosa with an infected lesion. Minor trauma at the site is believed to facilitate 
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infection of the basal epithelial cells. Although HPV transmission usually occurs via 
direct contact, normal intact skin or mucosa is resistant to inoculation by the virus. 
Oncogenic activity of HPV: 
HPV only infects stratified squamous epithelial cells (including skin and mucosa of 
genital tract, pharynx and anus), and does not enter blood circulation. In epithelial 
cells, HPV produces a number of proteins, including E6 and E7 oncoproteins 
produced by high-risk HPV, which are the only two HPV oncoprotein known until 
now. Overexpression of E6 and E7 oncoproteins generally requires viral DNA 
integration into the cell genome. The integrated viral genome is not complete and 
cannot produce progeny viruses by replication. However, production of excessive E6 
and E7 oncoproteins promotes the occurrence of cancers. Sustained overexpression of 
E6 and E7 oncoproteins in epithelial cells interrupts cell cycle, inhibits apoptosis, and 
activates telomerase, leading to the immortalization of cells and finally 
canceration(Galowayet al., 2015).  
 
  
Figure 3: Oncogenic mechanism 
of HPV 
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Table 1: Identified functions of the high-risk HPV oncoprotein E6 
ONCOPROTEIN E6 FUNCTIONS INVESTIGATORS & YEAR 
Cell immortalization Band et al., 1990 
Binding of E6-AP results in degradation of p53 Tommasino et al., 2003 
Antiapoptopic effect Thomas & Banks, 1998 
Chromosomal destabilization White et al., 1994 
Foreign DNA integration Kessis et al., 1995 
Enhancement of DNA mutagenicity Havre et al., 1995 
Activation of telomerase Klingelhutz et al., 1996 
Blockade of interferon Ronco et al., 1998 
E2F- regulated mitotic genes Thierry et al., 2004 
E6 I/E6 II gene expression Moodley et al., 2003 
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HPV infection leads to deregulation of the cell cycle. Regulation of protein expression 
in uninfected epithelium is shown in (Figure 5A). In the presence of high risk HPV 
(Figure 5B), regulation of proteins necessary for cell proliferation is altered, allowing 
HPV to stimulate S phase entry in the upper epithelial layers. In epithelium infected 
by high risk HPV, progression through the cell cycle is not dependent on external 
growth factors, but is stimulated by the E7 protein, which binds and degrades pRb and 
facilitates E2F mediated expression of cellular proteins necessary for S phase entry. 
Although p16 levels rise, normal feedback is bypassed as HPV- mediated cell 
proliferation is not dependent on cyclin D/cdk 4/6.  
The rise in the level of p14ARF which occurs in the absence of p16 mediated 
feedback, leads to the inhibition of MDM function and an increase in the level of p53. 
This is countered by E6, which associates with E6AP ubiquitin ligase in order to 
stimulate in degradation of the p53 protein and prevent growth arrest and or apoptosis. 
In low grade disease, E7 levels are carefully regulated. It is thought that E7 mediated 
cell proliferation can sometimes be inhibited as a result of association with p21 and 
Figure 4: cell cycle progression by high risk HPV type 
REVIEW OF LITERATURE 
 
19 
 
cyclin E/Cdk. The high levels of E7 found in cancer cells are thought to overcome this 
block by binding and inactivating the Cdk Inhibitor p21 
 
 
 
 
Koilocytes 
In 1951, a Canadian gynecologist cytologist J. Ernest Ayre, first described and 
illustrated squamous epithelial cells with a perinuclear “halo” in smears of the uterine 
cervix. In 1956 Koss and Durfee named the cytological changes as “koilocytes”(from 
Greek, a hollow cell). They defined koilocytes as the squamous cells with enlarged 
nuclei and sharply demarcated perinuclear clear zone, surrounded by a rim of 
cytoplasm. 
Syrjanenet al in 1983 stated that the role of cytoplasmic vacuolization in viral 
replication is unclear. However, it could contribute to the fragility of keratinocytes 
Figure 5 (A and B) shows deregulation of cell cycle by HPV 
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and release of viral-laden nuclei from HPV lesions. There is a movement of 
papillomavirus to the superficial layers of the epithelium that is facilitated by 
disturbing keratin integrity and assembly of cornified layer. 
 
 
 
Collectively these changes are called cytopathic effect. Some cells may display 
binucleation with nuclear atypia and are termed as “koilocytic dysplasia”. 
Classification of koilocytosis: 
In cervical neoplasias, koilocytosis has been classified as (Bethesda system, 2001) 
• Low squamous intraepithelial lesion: mild koilocytosis with mild dysplasia/cervical 
intraepithelial neoplasia (CIN1) 
• High squamous intraepithelial lesion: marked koilocytosis with moderate and 
severe dysplasias, carcinoma in situ/CIN 2 and 3 
 
 
Figure 6:Koilocytes in suprabasal layers of epithelium 
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Association of HPV with oral benign epithelial lesions: 
Miller and White, 1996 reviewed literature from 1983 to 1995 for the identification 
of the expression of HPV in oral mucosa, oral premalignant lesions and OSCC. They 
identified increasing frequency of HPV infection in normal mucosa (13.5%) 
leukoplakia (14.8%) and OSCC (26.2%). HPV was detected more readily with PCR 
and also in samples that were fresh and frozen rather than paraffin embedded. 
Miller and Johnstone, 2001conducted a meta-analysis of 94 articles published in 
Medline in English Literature to detect HPV in tissues or cells derived from normal 
oral mucosa, leukoplakia, carcinoma in-situ and oral cancer. The analysis was made 
by means of a random-effects model with and without adjustments for array 
sensitivity. The HPV was detected in 10% of normal oral mucosa, 22.2% of 
leukoplakia, 26.2% of carcinoma in situ, 29.5% of verrucous carcinoma and 46.5% of 
OSCC. 
Jimenez et al., 2001 used PCR technique in biopsy specimens of normal oral mucosa 
and cases with squamous papilloma, oral condyloma, oral verruca vulgaris and focal 
epithelial hyperplasia. HPV DNA was detected in 41% of squamous papilloma, 50% 
of oral verruca vulgaris, 100% of oral condyloma, 100% of Heck’s disease and 10% 
of normal mucosa. HPV 6 was the predominant type. 
Chen et al., 2002 used in situ-PCR to detect various HPV types in oral cancer 
associated with betel quid chewing and cigarette smoking in Taiwan. Their findings 
were as follows HPV 6 (11%), HPV 11 (3.7%), HPV 16 (85.7%) and HPV 18 
(71.4%). Using multivariate analysis, they showed that HPV infection and betel quid 
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chewing were independent risk factors in contrast to the hypothesis that when risk 
factors such as quid and HPV infection existed together they act synergistically. 
Sugiyama et al., 2003 used paraffin embedded sections amplified by PCR to detect 
the presence of HPV in normal oral mucosa, leukoplakia, OSCC (oral squamous cell 
carcinoma) and found that they were 36%, 61%, 35% respectively.  
Jayasooriya et al., 2004 reported two cases with multiple whitish nodules in the oral 
cavity diagnosed as Focal epithelial dysplasia (Heck’s disease) based on the 
histopathology. They identified PCR detected HPV DNA in one case using PCR. 
Role of HPV in oral epithelial dysplasia and potentially malignant disorders: 
Oral malignancy which is often preceded by preexisting oral lesions termed as 
potentially malignant disorders of the oral mucosa such as leukoplakia, oral 
submucous fibrosis and lichen planus. In the oral cavity, LR-HPV infection is 
associated with a variety of benign lesions including squamous cell papilloma, 
verruca vulgaris, condyloma acuminatum and focal epithelial hyperplasia, but can 
also be detected in potentially malignant epithelial lesions such as leukoplakia and 
erythroplakia(Nielson et al., 1996).  
HPV in leukoplakia: 
About 70-90% of oral leukoplakias are related to smoking and arecanut use, either 
alone or in combination and there is a direct relationship between the frequency and 
the duration of cigarette, pipe or cigar smoking and the prevalence of oral leukoplakia 
(Subba, 1995). The factors implicated in the pathogenesis of idiopathic leukoplakia 
are unknown. However, it is possible that infection of the oral epithelium with HPV 
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and excessive consumption of alcoholic beverages may be associated with oral 
Leukoplakia. But there is little evidence available to support the possible role of HPV 
infection and alcohol in the pathogenesis of oral leukoplakia. 
Dysplasia is more frequent in non-homogenous than in homogenous leukoplakia. It 
has a greater risk of carcinomatous transformation (20-25%) than homogenous 
leukoplakia (0.6-5%) (Reibel, 2003). Although the malignant transformation is highly 
associated with non-homogenous type of leukoplakia, HPV is found in association 
with homogeneous leukoplakia (Neilson,1996).Campisiet al.,examined the 
relationship in oral leukoplakia between HPV and some molecular predictors of 
malignant progression such as apoptosis markers (bcl-2 and survivin) and 
proliferation markers (proliferating cell nuclear antigen; PCNA). The risk of HR-HPV 
infection was found to be independently associated with survivin and PCNA 
expression, suggesting that these factors could be involved in HPV-mediated 
disorders of epithelial maturation. 
The role of HPV in the pathogenesis of oral leukoplakia and its progression to 
carcinoma is unclear since there is a low viral load in HPV cytopositive precancerous 
and cancerous oral lesions and viral integration is seldom found (Koskinen, 2003). It 
is possible that HPV DNA in oral leukoplakia and in oral squamous cell carcinoma 
may be oncogeneticallyinsignificant. Alternatively, the HPV may have superinfected 
keratinocytes already initially transformed and may thus additively or synergistically 
promote larger stages of transformation (Feller, 2009) 
Several HPV genotypes have been detected in precancerous oral lesions. High risk 
HPV genotypes in particular HPV 16, have been reported to be the most prevalent in 
leukoplakias, including proliferative verrucous leukoplakia (Ostwald, 2003). Other 
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reports implicated low risk rather than high risk HPV genotypes in oral leukoplakia 
(Miller, 2003) and yet others assert that oral leukoplakia is co infected with a variety 
of HPV genotypes (Bouda, 2003). 
D’cosatet alhad reported that HPV 16 may play a direct role in a certain proportion of 
oral cancer whereas subpopulation of oral cancers HPV 16 infection may be vital in 
the early events associated with development of potentially malignant oral lesions and 
the presence of the virus not essential in the progression of the oral lesion to frank 
malignancy. 
Miller and Johnstone had done meta-analysis of data from 94 studies which included 
4580 specimens. They reported that HPV detected in precancerous oral lesions is 2 to 
3 times greater and in oral squamous cell carcinoma it is 4 to 5 times greater than in 
normal mucosa.  
They suggested that there may be some link between HPV infection and oral 
precancerous lesions and cancerous lesions. HPV may play either an oncogenic role 
or a co oncogenic role in some HPV infected precancerous and cancerous epithelial 
neoplasms.Palefsky et al in 1995 described the contributory role of strains of HPV 16 
and 18 in pathogenesis of oral leukoplakia. 
Little is known about the E6 and E7 proteins of low risk HPV either with regard to 
their role in the pathogenesis of HPV infected oral leukoplakia or with regard to their 
role in the carcinomatous transformation of some leukoplakia. It is possible that as in 
other HPV related benign proliferative oral epithelial lesions, E6 and E7 proteins of 
low risk HPV types found in oral leukoplakia may stimulate supra basal post mitotic 
infected keratinocytes to re-enter theS phase of the cell cycle resulting in epithelial 
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proliferation and disturbed maturation without causing the genomic instability 
possibly associated with subsequent cell transformation. This mechanism may be a co 
determinant of the development of leukoplakia but there is no concrete evidence to 
support (Feller, 2012) 
Oral lesions caused by constant exposure to guthka are associated with high frequency 
of HPV infection which may be a risk factor for squamous cell carcinoma of the oral 
cavity. HPV frequency was 2.7% greater in chewers with more than10 years of habit 
compared to be less than 10 years. HPV prevalence has been reported to be twice as 
high in pre-malignant lesions as in normal mucosa and is nearly five times higher in 
oral squamous cell carcinoma. Its prevalence increases from normal to dysplasia and 
finally to cancer due to scraping and scratching caused by continuous chewing on 
guthka. The epithelium which lines the upper aero digestive tract is the main area 
from where the majority of the head and neck malignancies originate from, which 
includes the oral cavity, larynx and pharynx. The epithelial areas of the upper aero 
digestive tract display the greatest susceptibility to HPV due to the easy exposure of 
basal cells to HPV infection (Baiget al., 2012) 
There is an extreme variation in the reported prevalence of HPV infection in oral 
precancerous and cancerous lesions ranging from 0% to 100% (Gahravanian et al., 
2012). This is owing to differences in sampling and HPV detection methods to 
differences in ethnicity, geographic locations and sample size of the subjects 
examined and to in the inappropriate grouping together of different lesions from 
different anatomical locations of the mucosa of the upper aero digestive tract. 
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HPV in relation to oral submucous fibrosis: 
The association between non-malignant oral lesions (chronic inflammation, sub 
mucous fibrosis, leukoplakiaand squamous papilloma) and HPV are much less well 
understood. Studies show that there is a significant association of oral submucous 
fibrosis with these non-malignant lesions, HPV, betel quid chewing and smoking. A 
multivariate analysis showed that the betel quid chewing habit remained an 
independent factor for leukoplakia and squamous cell carcinoma (Chen, 2006).While 
comparing virus infection and histopathology of OSMF, no significant association 
between the various addiction habits and the presence of HR-HPV had been detected 
in OSMF (Mehrotra, 2010). 
Head and Neck cancers 
Roberto et al., 1998 determined the prevalence of HPV infection in head and neck 
cancers using frozen sections amplified by PCR. They found a prevalence of 11% 
HPV suggesting that chemical carcinogens play a more important role than HPV in 
cancer formation. 
Mork et al., 2001 in their study proposed HPV as a risk factor for head and neck 
cancer. They postulated that HPV DNA detection might lead to sampling errors in 
asymptomatic cases. They suggested that using capsid antibodies to HPV could be a 
reliable marker of previous and present HPV infection. The serum of 292 cases was 
examined and only 98 cases were positive from HPV capsid antibodies. In 228 of the 
biopsy specimens, HPV was detected in 160 tumor specimens. They suggested that a 
possible causative association between HPV and head and neck cancers could exist. 
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Herrero et al., 2003 in a multi-centric, case –control study of 1670 cases from 9 
countries found a prevalence of HPV DNA 16/18 in 3.9% oral squamous cell cancers 
and 18.9% oropharynx cancers. They used biopsy specimens stored in frozen 
condition and blood samples for detection of HPV DNA. HPV type 16 was found in 
89.3% of cases, HPV16 and 18 in 5.4%, only HPV18 in one case. They conclude that 
HPV acts as the etiologic agent in a small subgroup of oral carcinomas. 
Li et al., 2003 examined the expression and inactivation of genes operating within the 
p53 and pRb pathway, such as cyclin D1 and cyclin dependent kinase inhibitors p21, 
p16, p27 and also p53 and pRb proteins, in Tonsil cancer with HPV positivity / 
negativity and correlated it with the survival of the patient. Cell cycle proteins could 
not predict the recurrence and survival of the patient. Cases with HPV positive tumors 
were significantly less likely to have recurrence or die of the disease. Based on this 
they concluded that HPV positive tonsil cancers are a distinct biologic group. 
Gillison, 2004 suggested the fact that molecular changes for HPV positive head and 
neck carcinoma are different from other carcinomas and hence HPV positive cancers 
are considered a distinct entity. In normal oral keratinocytes when transfected with 
HPV 16 alone, it caused immortalization of the cells but did not form tumors in nude 
mice. On further exposure to tobacco it caused tumor formation. 
Zhang et al., 2004 were able to identify HPV DNA subtypes 16/18 in 55% normal 
mucosa and 74% in OSCC. Based on the previous studies the author feels that the use 
of late gene (L) primer may give negative results, because the L1 and L2 regions may 
be lost during the HPV DNA integration into host DNA. The prevalence of HPV was 
more in young cases and predominantly in males. The authors suggested that the HPV 
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alone is not a good predictor for progression to cancer because of its presence in 
normal mucosa. 
Tachezyet al., 2005 examined the prevalence and subtypes of HPV in oral and 
oropharyngeal cancer. HPV DNA was detected in 51.5% of cases. HPV16 was the 
predominant type. HPV 33 was also detected in three cases. Since there was no 
association with smoking or alcohol drinking the author concluded that head and neck 
cancer positive for HPV are a different group epidemiologically and etiologically. 
HPV in relation to OSCC: 
Syrjanen et al., 1983 suggested the presence of HPV virus both morphologically and 
immunohistochemically in pathogenesis of oral squamous cell carcinoma. Their 
analysis showed morphologic alterations in superficial layer such as hyperkeratosis, 
dyskeratotic superficial cells, Deep layers showed acanthosis and koilocytosis, which 
is pathognomonic of HPV infection. Individual cells showed single cell dyskeratosis 
and multinucleation. They also identified immunohistochemically the presence of 
HPV in cancer tissue. 
Miller et al., 1994 studied the prevalence of the subtypes of HPV DNA in 
deparaffinised oral carcinoma specimens on slides using in situ PCR. HPV 16 was 
detected in 69.2% of cases and HPV 18 in 28% of cases using in–situ PCR. HPV 
DNA was not detected in any specimens by in situ hybridization technique. 
Histomorphologic analysis by in–situ PCR of HPV altered epithelium (vacuolated 
cells) and in areas adjacent cancer tissue, did not show positive HPV DNA. 
Elaminet al., 1998 detected HPV in 14/28 cases of oral cancer and 4/12 cases 
premalignant lesions. Presence of HPV in premalignant lesions helped the authors to 
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come to a hypothesis that HPV may be an early event in carcinogenesis. No 
association was seen between HPV and the tumor grade. 
Shima et al., 2000 found a significant relationship between HPV 16 of and p53 
mutation in their study of oral squamous cell carcinoma. They suggest the HPV 16 
has a mutagenic effect in oral OSCC. No significant relationship was observed 
between HPV infection and p53 mutation on survival of the patient. 
Ibieta et al., 2005 in their study, found that HPV is a risk factor for oral squamous 
cell carcinoma. HPV infection, alcohol drinking and smoking are independent risk 
factors. They also suggested that women with cervical cancer should be studied for 
the status of HPV in the oral cavity. 
Prevalence of HPV induced oral cancers in India 
The prevalence of HPV in oral cancer has been documented in several studies from 
different geographical regions of India. However, the prevalence of HPV differs in 
different geographical regions with Indian subcontinent. The infection of HPV 16 is 
reported in 27% of oral cancer from north India whereas western part of the country it 
ranges from 25 to 31%. Multiple HPV infection was observed in about 14% of cases. 
The reports of HPV prevalence in oral cancer from southern India seems to be highly 
variable. The overall frequency of HPV infection has been reported to be 74% while 
41% showed multiple HPV infection. HPV type specific infection for HPV types 
6,11,16 and 18 was found to be 13,20, 42, and 47% respectively. 
There is sparse Indian literature describing HPV infection of the oral cavity in the 
general population and the two existing studies are highly discordant. In one, the 
saliva rinse of 396 normal individuals from various parts of North Karnataka was 
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collected and polymerase chain reaction (PCR) based high-risk (HR) HPV genotyping 
was carried out. It reported 2.75% were positive for HPV16 and 22% positive for 
HPV18 (Kulkammiet al.,2011). In another study, oral mucosal smears were prepared 
from 60 healthy individuals and PCR-based HR-HPV genotyping was carried out. It 
reported 65% of individuals to be positive for HPV16/18 (Pattanshettyet al., 2014). 
Western literature reports a low prevalence of HPV infection (<10%) in normal oral 
mucosa (Migaldiet al., 2011). There is not enough evidence to clearly establish the 
role of latent HPV infection of the oral cavity in normal individuals in the 
development of cancer. Western literature indicated an association between HR 
sexual behavior (oral sex and number of sexual partners) and HNSCC. Indian data are 
sparse in this respect as eliciting detailed sexual history is usually uncomfortable for 
the patients as well as the clinicians. Bahlet al. in 2014 reported HR sexual behavior 
in 58% of patients with oropharyngeal carcinoma who tested positive for HPV DNA, 
which was significantly higher than the HPV DNA negative cohort. 
Immunohistochemistry for viral proteins  
IHC for viral proteins such as E6 and E7 has been performed, however with low 
success rate due to poor sensitivity and specificity. Therefore, this method is not used 
for routine testing. However, recent studies investigating the possible use of E7 
staining in cervical cancer have shown promising results discriminating between high- 
and low-grade neoplasias(Faoroet al., 2013). 
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SOURCE AND COLLECTION OF DATA 
This study was conducted on archival tissue samples taken from the Department of 
Oral Pathology & Microbiology, KSR Institute of Dental Science and Research, 
Tiruchengode. A total of 45 samples that included 15 cases of oral epithelial 
hyperplasia, 15 cases of oral epithelial dysplasia and 15 cases of oral squamous cell 
carcinoma were included in the study. These archival tissues had been fixed in 
neutral buffered formalin, processed and embedded in paraffin wax. 
INCLUSION CRITERIA 
Tissue blocks of histopathologically diagnosed cases of oral epithelial hyperplasia, 
oral epithelial dysplasia and oral squamous cell carcinoma were included. 
EXCLUSION CRITERIA 
Tissue blocks of above-mentioned cases, with inadequate tissue were excluded. 
EQUIPMENTS AND MATERIALS USED IN THE STUDY 
Apart from armamentaria required for routine processing of soft tissues, the 
following equipments and materials were used for the immunohistochemical and 
hematoxylin and eosin staining. 
1. APES (3-Aminopropyltriethoxysilane) pre-coated slides 
2. Normal glass sides 
3. Microtome 
4. Xylene 
5. 100%, 90%, 70%, and 50% alcohol 
6. Distilled water 
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7. Citrate buffer (pH: 6) 
8. Pressure cooker 
9. Humidifying chamber 
10. Micropipettes with plastic disposable pipette tips 
11. Tris phosphate wash buffer (pH: 7.4) 
12. Peroxide block 
13. Power block 
14. Primary antibody – Anti E6 oncoprotein HPV 16/18 (Sigma Aldrich) 
15. Universal secondary kit (Biogenex) 
- 3% hydrogen peroxide block 
- secondary antibody 
- Streptavidin conjugated with horse radish peroxidase 
- Diluting buffer 
- Diaminobenzidine chromogen (DAB) 
16. Mayer’s Hematoxylin 
17. Harris Hematoxylin 
18. Eosin Yellow stain 2% w/v (Nice) 
19. Dibutylpthalate xylene (DPX) Mountant 
20. Cover slip 
21. Slide holding box 
22. Light microscope (Olympus CH20i) 
23. Antibody diluent solution (Abcam US) 
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REAGENT PREPARATION 
Dilution of primary antibody (Anti E6 HPV 16/18) 
The primary antibody was diluted to a ratio of 1:10 using antibody diluent solution 
(Abcam,US) 
Antigen retrieval (Sodium citrate) buffer (10 mmol sodium citrate,pH 6.0) 
 Tri-sodium citrate (dihydrate) -2.94g 
 Distilled water-1000ml 
 1mol hydrochloric acid 
All the above ingredients were mixed to dissolve. The pH was adjusted to 6.0 with1 
mol hydrochloric acid. 
Wash buffer - Tris buffer saline (TBS, pH 7.4) 
 Tris - 0.605gms 
 Sodium chloride - 8gms 
 1 mol Hydrochloric acid - 4.4ml 
All the above ingredients were mixed to dissolve. The pH was adjusted to 7.4 with 1 
mol Hydrochloric acid. 
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PREPARATION OF SECTIONS FOR IHC STAINING 
Sectioning: 
For immunohistochemistry, each section of about 3 to 4 μm thickness was prepared 
by using a semiautomatic microtome. The sections were placed on APES pre-coated 
slides. The slides were preserved in a slide holding box until they were stained 
Deparaffinization: 
The sections were deparaffinized by heating on the slide warmer at 60°C for one 
and halfhours. The sections were then dewaxed in 2 changes of xylene, each lasting 
15 minutes. 
Rehydration: 
The sections were rehydrated in decreasing grades of alcohol (100%, 90%, 70%, 
and 50%), 5 minutes each and kept under water for 10 minutes. 
Antigen Retrieval: 
fer (pH 6.0) was added into the pressure cooker 
and brought to boil (without securing the lid) 
the lid was sealed 
The pressure cooker was allowed to reach full pressure, then left for about 20 
minutes 
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s buffer (pH 7.4) for 5 
minutes 
IHC STAINING PROCEDURE: 
All the reagents stored in the refrigerator were brought to room temperature prior to 
immunostaining. All the incubations were performed at room temperature using a 
humidifying chamber unless otherwise mentioned. The tissue sections were not 
allowed to dry at any point during the staining procedure. 
Step 1: Endogenous peroxidase blocking: 
Sections were covered with peroxidase block for 10 minutes to prevent nonspecific 
binding of secondary antibody. The slides were then rinsed twice with wash buffer 
for 5 minutes. 
Step 2: Power Block: 
Antibodies may attach nonspecifically to highly charged sites. Toprevent this, 
power block was used to avoid cross reactions and to reduce nonspecific binding. 
The sections were covered with power block solution for 10 minutes. 
Step 3: Incubation with primary antibody: 
Excess buffer was tapped off and the sections were incubated overnight with mouse 
monoclonal Anti-E6 oncoprotein HPV 16/18 Antibody (Sigma Aldrich) at 1:10 
dilution at 4°C. 
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Step 4: Super enhancer application 
The sections were covered with super enhancer for 20 minutes and washed with tris 
buffer for 5 minutes and excess was wiped out using blotting paper. 
Step 5: Secondary antibody application: 
The slides were washed and treated with secondary antibody tagged with 
horseradish peroxidase enzyme (HRP) for 30 min[Biogenex]. 
Step 6: Substrate chromogen application: 
The slides were then washed with phosphate buffer saline and immunostaining was 
developed by treatment with freshly prepared DAB (3-diaminobenzidene tetra 
hydrochloride) solution for 5 minutes following which they were washed in distilled 
water to remove excess chromogen. 
Step 7: Counter stain: 
The slides were immersed in Mayer’s hematoxylin for 30 seconds, and bluing was 
done using distilled water 
Step 8: Dehydration and cleaning: 
The sections were dehydrated in 100% alcohol, followed by clearing in xylene. 
Step 9: Mounting: 
The sections were mounted using dibutylpthalatexylene (DPX), a non-aqueous 
permanent mounting medium. 
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POSITIVE CONTROL 
 Histologically diagnosed cases of cervical carcinoma were included as positive 
controls 
 For each batch of immunohistochemical staining, one positive control slide of 
cervical cancer and one negative control slide without incubating with primary 
antibody were also stained concurrently 
 It was ensured that the positive control slide showed specific positive 
immunoreactivity to Anti E6 HPV 16/18 antibody in each batch. 
 In the event of positive control showing negative immunoreactivity, the entire 
batch was rejected. 
H&E STAINING PROTOCOL 
Routine hematoxylin and eosin staining protocol was carried out 
INTERPRETATION OF STAINING: 
The expression of E6 oncoprotein HPV 16/18 were observed in cytoplasm and 
nucleus of the epithelium in the sections as follows: 
 Presence of brown colored end product at the site of target antigen was 
considered as positive immunoreactivity 
 The immunostained slides were observed for positivity under 4x/ 10x/ 40x 
magnifications and recorded with a high-quality photomicrograph 
Percentage of positive cells was calculated in five high power fieldsas follows: 
Percentage of positive cells=   
Number of positive nuclei 
Total number of nuclei 
X 100 
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Intensity of the staining was graded as follows 
 Negative expression 
 Mild expression 
 Moderate expression 
 Intense expression 
KOILOCYTE COUNTING: 
H and E stained sections were examined for the quantification of koilocytes. 
Analysis was carried out on the basis of simplified histological definitions of 
koilocytosis established by Reid et al. (1982). Cells showing the following features 
were considered as koilocytes: 
 Large cells with perinuclear haloes 
 In association with nuclear atypia like pyknosis and binucleation. 
Koilocyte quantification: 
Average number of koilocytes per high power field was assessed for each case. 
Presence of one or greater than one number of koilocyte per high power field was 
considered to be positive for koilocytosis. 
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STATISTICAL METHODS 
All the parameters were tabulated and assessed for statistical significance using 
statistical package for social science (SPSS) software version 20. The difference in 
the expression of E6 oncoprotein HPV 16/18 and the presence of koilocytosis in oral 
epithelial hyperplasia, dysplasia and oral squamous cell carcinoma were statistically 
analyzed using Fisher’s exact test to compare individual groups against each other, 
followed by Cramer’s V test to assess the strength of association between the 
parameters. 
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Figure 7: Photograph showing materials used for IHC staining 
Figure 8: Photograph showing materials used for H&E staining 
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Figure 10: Photograph showing universal secondary antibody kit 
Figure 9: Photograph of primary antibody (anti E6 oncoprotein of HPV 16/18) 
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A total number of 45 cases, comprising 15 cases of oral epithelial hyperplasia [Group 
I], 15 cases of oral epithelial dysplasia [Group II] and 15 cases of oral squamous cell 
carcinoma [Group III] were included in the study. The distribution of the cases is 
presented in Table 2 
Table 2: Distribution of cases among the three study groups 
GROUPS NUMBER OF CASES 
Oral epithelial hyperplasia 15 
Oral epithelial dysplasia 15 (Mild - 4; Moderate - 10; Severe - 1) 
Oral Squamous cell carcinoma 
15 (Well differentiated - 6; Moderately 
differentiated - 8; Poorly differentiated - 1) 
 
Percentage of positivity of E6 HPV 16/18 in the different study groups 
Immunohistochemical expression of E6 oncoprotein HPV 16/18 was assessed in all 
the three groups. 
GROUP I: 
In this group none of the 15 cases of oral epithelial hyperplasia showed 
immunopositivity for E6 oncoprotein HPV 16/18 and the total percentage of positivity 
was 0%. 
GROUP II: 
In this group none of the 15 cases of oral epithelial dysplasia,irrespective of their 
grade, showed immunopositivity for E6 oncoprotein HPV 16/18 and the total 
percentage of positivity was 0%. 
GROUP III: 
Four out of 15 cases of oral squamous cell carcinoma showed immunopositivity for 
E6 oncoprotein HPV 16/18 and the percentage of positivity was 27%. 
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Table 3: Cross tabulation of positivity for E6 HPV16/18 with the different study 
groups 
 
 
Immunopositivity of E6 oncoprotein HPV16/18 in different groups was compared. 
Results obtained were analyzed using Fisher’s exact test (Table 3). The p value 
obtained was 0.027, showing that there is a statiscally significant difference in 
immunopositivity among different groups. Using Cramer’s V value (0.442) to 
estimate the strength of association (Table 3), we could determine that there was a 
moderately strong association between the study groups and immunopositivity of E6 
oncoprotein HPV 16/18. 
 
IHC Positivity 
Total 
No Yes 
Group 
OEH 
Count 15 0 15 
% within Group 100.0% 0.0% 100.0% 
% within IHC positivity 36.6% 0.0% 33.3% 
OED 
Count 15 0 15 
% within Group 100.0% 0.0% 100.0% 
% within IHC positivity 36.6% 0.0% 33.3% 
OSCC 
Count 11 4 15 
% within Group 73.3% 26.7% 100.0% 
% within IHC positivity 26.8% 100.0% 33.3% 
% of Total 24.4% 8.9% 33.3% 
 Value Exact Sig. (2-sided) 
Fisher's Exact Test 6.419 .027 
Symmetric Measures 
 Value Approx. Sig. Exact Sig. 
Cramer's V .442 .012 .027 
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Percentage of positivity among the different grades of oral squamous cell 
carcinoma: 
On examining the immunopositivity within different grades of oral squamous cell 
carcinoma, we found that two out of 6 cases of well differentiated and two out of 8 
cases of moderately differentiated squamous cell carcinoma showed 
immunopositivity. However, the lone case of poorly differentiated squamous cell 
carcinoma that was examined was negative of E6 oncoprotein HPV 16/18 
 
Table 4: Cross tabulation of positivity for E6 HPV16/18 with the different grades 
of oral squamous cell carcinoma 
 
 
IHC Positivity 
Total 
No Yes 
Group 
WDSCC 
Count 4 2 6 
% within Group 66.7% 33.3% 100.0% 
% within IHC positivity 36.4% 50.0% 40.0% 
MDSCC 
Count 6 2 8 
% within Group 75.0% 25.0% 100.0% 
% within IHC positivity 54.5% 50.0% 53.3% 
PDSCC 
Count 1 0 1 
% within Group 100.0% 0.0% 100.0% 
% within IHC positivity 9.1% 0.0% 6.7% 
 Value Exact Sig. (2-sided) 
Fisher's Exact Test .782 1.000 
Symmetric Measures 
 Value Approx. Sig. Exact Sig. 
Cramer's V .185 .774 1.000 
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Immunopositivity of the different grades of squamous cell carcinoma was statistically 
analyzed using Fisher’s exact test. The p value obtained was 1.000 showing that there 
was no statiscally significant difference in immunopositivity among different grades 
of oral squamous cell carcinoma (Table 4). Using Cramer’s V value (0.185), we 
determined that there was a very weak association between the immunopositivity of 
E6 oncoprotein HPV 16/18 and grading of oral squamous cell carcinoma (Table 4). 
 
Table 5: Over all comparison of intensity of E6 HPV 16/18 expression in 
different grades of oral squamous cell carcinoma group 
Group 
Totalno of 
cases 
Mild (%) 
Moderate 
(%) 
Severe 
(%) 
No expression 
(%) 
Oralsquamous cell 
carcinoma 
15 4 (27%) 0 (0%) 0 (0%) 11 (73%) 
 
The intensity of staining for E6 oncoprotein HPV 16/18 was assessed subjectively as 
mild, moderate and intense. We found that, all four cases that showed 
immunopositivity for E6 oncoprotein took up only mild intensity of the stain 
irrespective of the group or subgroup they belonged to. 
Quantification of immunopositivity was also done by calculating the average number 
of cells per high power field that were positive for E6 stain. We found that: 
 One case of well differentiated squamous cell carcinoma showed 4% positive 
nuclei per high power field 
 One case of well differentiated squamous cell carcinoma showed 23% positive 
nuclei per high power field 
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 One case of moderately differentiated squamous cell carcinoma showed 4% 
positive nuclei per high power field 
 One case of moderately differentiated squamous cell carcinoma showed 18% 
positive nuclei per high power field  
Percentage of positivity of koilocytosis in the three groups 
Total number of koilocytes was evaluated in all the three groups. Average number of 
koilocytes per high power field was assessed for each case. Presence of one or greater 
than one number of koilocyte per high power field was considered to be positive for 
koilocytosis. 
 
GROUP I: 
In this group, five out of 15 cases of oral epithelial hyperplasia showed positivity for 
the presence of koilocytes and the total percentage of positivity for koilocytosis was 
33.33%. 
 
GROUP II: 
In this group, out of 15 cases of oral epithelial dysplasia, two cases showed positivity 
for the presence of koilocytes and the total percentage of positivity was 13.33%.  
 
GROUP III: 
In this group five out of 15 cases of oral squamous cell carcinoma, showed positivity 
for the presence of koilocytes and the total percentage of positivity was 33.33%.  
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Table 6:Crosstabulation of koilocytosis with the different study groups 
 
 
We compared the presence of koilocytosis among the cases in all the three study 
groups. The result obtained was statistically analyzed using Fisher’s exact test (Table 
6). The p value obtained was 0.414. suggesting that there was no significant 
difference of positivity of koilocytosis between the different groups. Using Cramer’s 
V value (0.213), we found a weak association between the positivity of koilocytosis 
and different groups (Table 6). 
 
  
 
 
Koilocytosis 
Total 
No Yes 
Group 
OEH 
Count 10 5 15 
% within Group 66.7% 33.3% 100.0% 
% within Koilocytosis 30.3% 41.7% 33.3% 
OED 
Count 13 2 15 
% within Group 86.7% 13.3% 100.0% 
% within Koilocytosis 39.4% 16.7% 33.3% 
OSCC 
Count 10 5 15 
% within Group 66.7% 33.3% 100.0% 
% within Koilocytosis 30.3% 41.7% 33.3% 
 Value Exact Sig. (2-sided) 
Fisher's Exact Test 2.098 .414 
Symmetric Measures 
 Value Approx. Sig. Exact Sig 
Cramer's V .213 .360 .522 
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Percentage of positivity of koilocytosis in different grades of oral squamous cell 
carcinoma 
On assessing the koilocytosis positivity within different grades of oral squamous cell 
carcinoma we found that one out of 6 cases of well differentiated squamous cell 
carcinoma and three out of 8 cases of moderately differentiated squamous cell 
carcinoma showed positivity for koilocytosis. The only case of poorly differentiated 
squamous cell carcinoma that was examined for positivity of koilocytosis also showed 
to be positive. 
Table 7: Crosstabulation of koilocytosis with the grades of oral squamous cell 
carcinoma 
 
Koilocytosis 
Total 
No Yes 
Group 
WDSCC 
Count 5 1 6 
% within Group 83.3% 16.7% 100.0% 
% within Koilocytosis 50.0% 20.0% 40.0% 
MDSCC 
Count 5 3 8 
% within Group 62.5% 37.5% 100.0% 
% within Koilocytosis 50.0% 60.0% 53.3% 
PDSCC 
Count 0 1 1 
% within Group 0.0% 100.0% 100.0% 
% within Koilocytosis 0.0% 20.0% 6.7% 
 Value Exact Sig. (2-sided) 
Fisher's Exact Test 2.550 .254 
Symmetric Measures 
 Value Approx. Sig. Exact Sig. 
Cramer's V .433 .245 .254 
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We compared the positivity of koilocytosis among the different grades of oral 
squamous cell carcinoma. Using Fisher’s exact test, the p value obtained was 0.254 
(Table 7). This showed that there was no significant difference in the prevalence of 
koilocytosis between the different grades of oral squamous cell carcinoma. Using 
Cramer’s V value (0.433), we determined that the strength of association between the 
positivity of koilocytosis and different grades of oral squamous cell carcinoma was 
moderately strong (Table 7). 
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Figure 11: Photomicrograph showing immunopositivity for E6 oncoprotein HPV 16/18 in 
cervical cancer (positive control). (40x) 
 
Figure 12: Photograph showing immunopositivity for E6 oncoprotein HPV 16/18 with mild 
expression in moderately differentiated squamous cell carcinoma. (40x) 
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Figure 13: Photomicrograph showing immunopositivity for E6 oncoprotein HPV 16/18 with mild 
expressionin well differentiated squamous cell carcinoma (40x) 
 
Figure 14: Photomicrograph showing koilocytes in H and E staining. (40X) 
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Viruses have been identified as etiological agents in several types of human cancers. 
High-risk types of human papilloma viruses (16 and 18) have been established as the 
cause of invasive cervical cancer and anogenital carcinomas. An increasing evidence 
implicating viruses as etiological agents in the development of cancers of the upper 
aero digestive tract is present in the literature (Devita,2001). The role of HPV as an 
etiological agent in oral cancer is supported by the fact that HPV DNA is present in 
oral cancer tissue and the observation that high risk HPV virus can also immortalize 
and transform normal oral epithelial cells. In this background the present study was 
conducted to detect the presence of HPV types 16 and 18 in oral epithelial 
hyperplasia, dysplasia and oral squamous cell carcinoma. 
In this study the expression of E6 oncoprotein of human papilloma virus 16/18 and 
the total number of koilocytes was evaluated and compared in the different study 
groups. This study comprised of 45 cases which included 15 cases of oral epithelial 
hyperplasia, 15 cases of dysplasiaand 15 cases of oral squamous cell carcinoma 
selected from the archives of our department.  
Immunostaining was done using the monoclonal antibody for E6 oncoprotein 
HPV16/18 raised in mouse. It was then quantified by calculating the percentage of 
cells that had taken up the stain. The intensity of the expression was categorized as 
negative, mild, moderate and intense in all the three different groups based on a 
subjective interpretation of how dark the stain had taken up. The values from the 
different groups were tabulated and analyzed statistically. 
H and E staining was done for the evaluation of koilocytes. Identification of 
koilocytes was carried out based on the simplified histological definitions of 
koilocytosis established by Reid et al., 1982.The prevalence of koilocytes was 
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quantified based on the average number of koilocytes per high power field for each 
case. Presence of one or greater than one number of koilocyte per high power field 
was considered to be positive for koilocytosis. 
Prevalence of HPV 16/18 in oral epithelial hyperplasia 
In the present study none of the fifteen cases of oral epithelial hyperplasia showed 
immunopositivity for E6 oncoprotein HPV 16/18 and the total percentage of positivity 
was 0%. 
Low prevalence of HPV in normal oral epithelia have been reported in several studies 
in the past. Our results are in accordance withEsquenazi et al.who had done a study 
in identifying the frequency of human papilloma virus DNA in normal healthy 
mucosa using PCR. They found that none of the one hundred volunteers with normal 
healthy mucosa were positive for HPV. They concluded that the negativity was 
mainly because these individuals belonged to high socio-economic status, were well-
nourished and followed a disciplined life style. 
Ostwald et al. had done a study in detectinghuman papillomavirus DNA in oral 
squamous cell carcinomas and normal mucosa and found out a very low prevalence of 
about 1% HPV DNA in patients with healthy oral mucosa.  
Giovanelli et al. had done a study determining the presence of HPV 16/18 in oral 
squamous cell carcinoma, potentially malignant lesions and in normal controls. They 
found that only 5.5% of normal controls showed positivity. 
Herberet al. assessed the involvement of E6 and E7 oncoproteins of HPV16 in the 
pathogenesis of squamous epithelial hyperplasia and carcinoma in mice. They found 
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that E7 oncoprotein of HPV, rather than E6,was responsible for the non-neoplastic 
proliferation of squamous epithelial cells.  
Young and Minperformed in situ DNA hybridization analysis in 23 samples of 
ordinary benign keratosis and found that none of the 23 cases were positive for HPV 
DNA. They concluded that biotinylated DNA ISH was more sensitive to detect HPV 
than IHC but less sensitive than radiolabelled DNA ISH and PCR. 
Bumrungthai et al.  had done a study in detecting HPV DNA in normal healthy 
volunteers using PCR and found very low prevalence (3.7 %) of HPV DNA in 594 
cases. 
Contrary to our findings,in their review of literature to define the role of HPV in 
pathogenesis of oral squamous cell carcinoma, Miller et al. found high prevalence of 
HPV 16 and 18 in normal oral mucosa (51.3%). They suggested that HPV may 
remain latent in oral epithelium at low levels for long periods of time before clinical 
andhistologic disease results and that the HPV type alone was not a reliable predictor 
of malignant progression. Terai et al. had also noted the highest prevalence of HPV 
DNA of about 81% using PCR in normal oral cavity of adults. They hypothesized that 
the low humanpapilloma virus copy numbers detected in normal oral mucosa in other 
studies suggest that persistent or transient human papilloma virus infection of the 
mucosa of the oral cavity occurs frequently. 
We could infer that the reasons for the lack of immunopositivity in oral epithelial 
hyperplasia in our study, as suggested by Herber et al.  could be because benign 
epithelial proliferation is the result of E7 oncoprotein and not E6. It is possible that 
E6 might not have a considerable role in pathogenesis of epithelial hyperplastic 
lesions. Also, as stated by Young et al.  it could be due to lack of sensitivity of IHC 
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technique for HPV detection. In addition to this, it is a well-known fact that benign 
lesions in oral cavity are mainly because of low risk HPV types rather than high risk 
HPVs like 16 and 18 that were examined for in our study. 
Prevalence of HPV 16/18 in oral epithelial dyplasia 
In the past few decades, there has been speculation worldwide about the role of HPV 
in the pathogenesis of head and neck squamous cell carcinoma (HNSCC). The most 
commonly detected HPV is HPV16 which accounts for 90% of the HPV DNA-
positive cases in HNSCC, followedby HPV18 and other high-risk subtypes. However, 
the detection rate of HPV in OSCC and oral potentially malignant disorders varies 
widely and remains controversial.  
In our study, we found that none of the 15 cases of oral epithelial dysplasia 
demonstrated immunopositivity for E6 oncoprotein HPV 16/18 irrespective of their 
grading. 
Our findings corroborate the findings ofLin et al.who had done a similar study in 
verrucous hyperplasia and verrucous carcinoma and reported a 0.3% 
immunopositivity in verrucous hyperplasia lesions. They stated that this might be due 
to either a low sensitivity of E6 oncoprotein HPV 16/18 or a scant expression of HPV 
16/18 E6 protein or negative participation of E6 oncoprotein of high-risk types in 
causing verrucous hyperplasia. 
Our study findings are also similar to the results of Chang et al. who could not detect 
the presence of HPV 16/18 in their oral verrucous carcinoma and oral verrucous 
hyperplasia samples by polymerase chain reaction (PCR). 
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Zeuss et al. had done in situ hybridization for detection of HPV16/18 in 15 cases of 
oral epithelial dysplasia and reported 0% positivity. They concluded that negativity 
might be due to the fact that 
1. The lesions studied may not have a viral cause 
2. The HPV types found in these lesions may contain different, poorly related 
genomic sequences compared with the sequences in the probe “cocktail”;  
3. The biotinylated probes and low-stringency conditions used may not be 
sensitive enough to detect low viral copy numbers 
4. Transformed cells may contain altered viral DNA not detectable by the probes 
used 
Our results were compatible with those of Fouretet al. who found 0% positivity in 15 
cases of oral epithelial dysplasia and claimed that though E6 is considered to be 
consistently retained in cancerous cells, variations in the location of the lesion, 
grading, clinical presentation and staging of the lesion will influence the prevalence of 
HPV. 
Similarly,Ha et al. examined 102 cases of premalignant lesions in oral cavity for the 
presence of HPV 16/18 using PCR and found HPV DNA was detected in 1 of 102 
premalignant lesions (0.98%) and concluded that high risk HPVs will rarely 
contribute to malignant transformation. 
However, in a study byElamin et al. toidentify the prevalence of HPV infection in 
premalignant and malignant lesions using PCR, they detected HPV DNA in 33% of 
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premalignant lesions. They suggested that HPV infection may be an early event in the 
malignant transformation of oral SCC. 
The absence of HPV in premalignant lesions in our study could be either due to the 
negative role of virus in these lesions as suggested by Zeuss et al. or due to lack of 
participation of high-risk HPVs in particular. It could be also because of lack of 
sensitivity of IHC in detecting the E6 proteins. The presence of other types of HPV 
might also be a causative factor in pathogenesis of premalignant lesions which are 
yet to be studied. 
Prevalence of HPV 16/18 in oral squamous cell carcinoma 
In our study, the third group included 15 cases of oral squamous cell carcinoma of 
different grades [well differentiated squamous cell carcinoma - 6; moderately 
differentiated - 8; poorly differentiated - 1]. Out of 15 cases, only 4 showed 
immunopositivity to E6 oncoprotein of HPV 16/18. These 4 cases included 2 cases of 
well differentiated carcinoma (33.33%) and 2 cases of moderately differentiated 
squamous cell carcinoma (25%). 
This finding was similar to that of Elamin et al who had done a study in identifying 
the prevalence of HPV infection in premalignant and malignant lesion using PCR. 
Theydetected HPV DNA in 14 out of 28 cases of oral squamous cell carcinoma 
(50%), but they could not find any association between viral infection and tumour 
grade or stage. They also added that despite the high prevalence of HPV in their study 
and in other reported cases of oral SCC, there was no direct evidence that HPV is one 
of the oncogenes involved in the malignant transformation of oral keratinocytes. 
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Qi et al.had found 18.3%positive cases of HPV 16/18 using IHC and 40% using ISH 
in esophageal squamous cell carcinoma and concluded thatthe discrepancy of two 
HPV detecting methods might be due to the fact that, the IHC method for HPV16/18 
E6 is only tested for the subtype of HPV16/18 E6 proteins, while HPV DNA cocktail 
probe for ISH has a wide spectrum; secondly, HPV DNA is more constant than their 
proteins in the paraffin tissues. 
Lingen et al.reported detection rate of high-risk HPV DNA of about 6.6 % and HPV 
mRNA of about 5.9%in OSCC. They claimed that mRNA or oncoproteins of HPV E6 
and E7 wereless commonly found than the DNA. 
Ilahi et al.had done a study in cervical cancer using both PCR and IHC and found out 
a co-infection of HPV 16 and 18 in only 8% of cases. They stated that E6 expression 
was higher in well differentiated samples and it reduced with level of differentiation. 
Cruz et al. had done a study in identifying age-dependence of human papillomavirus 
DNA presence in oral squamous cell carcinomas and concluded that the infection by 
other high-risk HPV subtypes such as 31, 33, 35 (i.e. other than HPV 16 and HPV 18) 
may account for the OSCC cases whose ages were below the age group of 60 years.  
Yasuda et al. had studied the infection and malignant transformation of human 
papilloma virus in oral squamous cell carcinoma and found out positivity in 12 out of 
21 cases of well to moderately differentiated (57%) and 4 out of 8 cases of poorly 
differentiated squamous cell carcinoma (50%). 
Although HPV 16 and 18 are suggested to be involved in oral cancer, their rates of 
detection in oral cancer are lower than in cervical cancer or pharyngeal cancer. Recent 
studies have shown the presence of HR-HPV in a fraction of oral pre-malignant and 
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malignant lesions.This may suggest a role of HPV in only a portion of oral 
malignancies, which is contrary to the cervical regionwhere its association is noted in 
almost all the cervical malignancies (Remmnik et al.). 
Hobes et al in their systemic review and meta-analysis in HPV head and neck cancer 
inferred that HPV 16 is the strongest causative agent for tonsillar cancer whereas it 
has weakest association with oral and laryngeal squamous cell carcinoma. They 
concluded that heterogeneity could be due to the method of viral detection employed. 
Pyssri et al. reviewedthe literature to determine the role of HPV in cervical cancer 
and head and neck squamous cell carcinoma. They stated that HPV have been 
detected in a variable proportion of HNSCC from 10% to 100%.They added that the 
disparity in the prevalence of HPV detection rate could be due to differences in 
anatomic locations of tumors or the techniques used in detecting HPV-DNA. 
In our study while comparing the percentage of immunopositivity of E6 oncoprotein 
HPV 16/18 among positive cases of well and moderately differentiated squamous cell 
carcinoma, we found that 23% and 4% of cells showed positivity in well differentiated 
squamous cell carcinoma while 18% and 4% of cells showed positivity in moderately 
differentiated squamous cell carcinoma cases. 
Tagle et al. had studied the expression of E6, p53 and p21 proteins and physical state 
of HPV16 in cervical cytologies with and without low grade lesions. According to 
them, an elevated E6 expression is an early event of cervical carcinogenesis due to the 
viral integration into the host genome. A similar trend of stronger E6 expression in the 
low-grade (well differentiated) was observed in our study. We could observe that 23% 
of cells showed immunopositivity in one case of well differentiated grade as 
compared only 18% of cells in moderately differentiated carcinoma. In our study, 
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poorly differentiated squamous cell carcinoma did not show any immunopositivity to 
E6 oncoprotein HPV 16/18. 
The difference in HPV detection in different grades of oral squamous cell carcinoma 
in our study could be due to various factors. Firstly, oral cavity is in direct contact 
with carcinogens present in tobacco and alcohol, making them the primary cause of 
oral carcinogenesis. Secondly, the low prevalence of oral HPV infection might be due 
to the body's immune response, like immunoglobulin IgA and proteolytic enzymes in 
the saliva that protect the oral mucosa from viral infections (Milletic et al.). Although 
the oral mucosal epithelium resembles the epithelium of the genital tract (Thompson 
et al.), antimicrobial action of saliva, along with its cleansing and lubricating 
properties, may reduce the possibility of virus entry into the oral epithelial cells by 
reducing the contact period of the virus with the oral mucosa. As suggested by Pyssri 
et al. the low prevalence of positivity in our study might also be due to lack of 
technical sensitivity. IHC is less sensitive when compared to ISH in the detection of 
HPV. It might also be because of the involvement of other high-risk types of HPV in 
oral carcinomas rather than types 16 and 18. 
DISCUSSION 
 
61 
 
Koilocytosis: 
Koilocytosis is the most common cytomorphologic change associated with viral 
infections and is considered by pathologists to be a major histopathologic feature for 
the determination of HPV infection. However,the clinical connotation and probability 
for malignant risk and its relationship with koilocytosis needs to be investigated 
further. 
Koilocytosis in oral epithelial hyperplasia and its comparison with IHC results 
In the present study, out of 15 cases of oral epithelial hyperplasia, 5 cases showed the 
presence of koilocytes (33.33%). However, none of the 5 cases which displayed 
koilocytic epithelial changes were positive for E6 oncoprotein HPV 16/18.  
D’Souza et al. had done a study in detecting HPV by immunohistochemistry in 
sinonasal papilloma and found that 3 cases showed the presence of koilocytes in their 
histopathology but were negative for HPV antigen by IHC and 1 case showed 
positivity for HPV antigen and negative for the presence of koilocytes. They 
concluded the positivity of koilocytes but negativity for HPV antigen might be 
because of involvement of different types of HPV other than 6,11 and 18. They also 
added that positivity of HPV antigen and negativity for koilocytic changes might be 
due to the fact that it takes time for the classical koilocyte to develop.  
Lawson et al. in their study for identifying the prevalence of koilocytes in breast 
carcinoma claimed that it should not beassumed that the presence of koilocytosis in 
normal breast tissuescommonly leads to breast cancer. Human papilloma 
virusinfections may be common in the breast, but consequentcancer may be rare. 
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Lack of immunopositivity in our five cases that showed koilocytosismight be because 
of the fact that there are different types of HPVs which produce koilocytic changes. 
Some other HPV types rather than the high-risk types might have been involved in 
these cases and produced the cytopathic changes. 
Koilocytosis in oral epithelial dysplasia and its comparison with IHC results 
In this group 2 out of 15 cases of oral epithelial dysplasia were identified as positive 
cases of koilocytosis (13.33%). Both the cases were negative for expression for E6 
oncoprotein of HPV 16/18 using IHC. 
Contrary to our study results,Allen et al. in their detailed study of casesdiagnosed as 
severe epithelial dysplasia of oral mucosa, concluded that ‘oralkoilocyticdysplasia’ 
(OKD) represented a unique pathological entity and thepresence of HPV could be 
predicted under light microscopy with 80% accuracy. 
The absence of koilocytes and negative expression of E6 HPV 16/18 in most of our 
study samples of oral epithelial dysplasiasuggests that dysplastic lesions in our study 
might have been caused due to some other factorsrather than high risk HPVs. 
Koilocytosis in oral squamous cell carcinoma and its comparison with IHC 
results 
In this group,five out of 15 cases of oral squamous cell carcinoma were identified as 
positive cases of koilocytosis. One of these five cases, one case was well 
differentiated (17%), three were moderately differentiated (38%) and one case was 
poorly differentiated squamous cell carcinoma (100%). However, none of the cases 
showed immunopositivity for E6 oncoprotein HPV 16/18 using IHC. 
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Smitha et al.on the contraryfound the presence of koilocytes in 14/31 cases of well 
differentiated and in 11/24 cases of moderately differentiated squamous cell 
carcinoma. They suggested that thepresence of koilocytes was reliable for the 
detection of HPV presence in routine histopathology in OSCCs. 
Khangura et al.  in 2013 had done a study in identifying the involvement of HPV in 
OSCC and found a statistically significant differencefor koilocytes between HPV 
(16/18)positive and negative cases. They concluded that koilocytosis can be reliably 
used as markers for the diagnosis of HPV in OSCC.  
Our results are in accordance with Miyahara et al. who compared histopathological 
analysis with PCR to predict the presence of HPV infection inOSCC biopsy tissues 
and found that the presence of koilocyteswas unreliable for the detection of HPV 
presence in oral andoropharyngeal SCC. 
In our study, none of the 5 cases of koilocyte positivity showed immunopositivity for 
E6 oncoprotein of HPV 16/18.It is possible that the samples that were positive for 
HPV 16/18 but negative for koilocytosis might be due to the longer time taken for the 
formation of koilocytes. Koilocytosis might be an unreliable marker of HPV infection. 
Although the sample size for different grades of oral squamous cell carcinoma in our 
study is very small, we could find a gradual increase in the prevalence of koilocytosis 
as we progress from well differentiated to poorly differentiated grade. It is likely that 
this change could be due to prevalence of HPV in these cases. However, using IHC, 
we found that none of the cases were positive for E6 oncoprotein of HPV 16/18. 
Probably investigations to identify HPV DNA using PCR or ISH could give us better 
correlation between koilocytes and HPV prevalence in different grades of oral 
squamous cell carcinoma. 
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Expression of E6 oncoprotein of HPV 16/18 was evaluated in oral epithelial 
hyperplasia, dysplasia and oral squamous cell carcinoma. Fifteen samples in each 
group were included in the study. 
Immunostaining was done using anti E6 oncoprotein for HPV 16/18 primary antibody 
and number of samples that had been taken up the immunopositive expression was 
evaluated. The intensity of staining was also graded as mild, moderate and intense. 
The presence of koilocytosis was also assessed in H and E stained sections of each 
sample. Data obtained were tabulated and analyzed statistically. 
Comparison of immunopositivity with koilocytosis was done among all the groups 
and also individually within the subsets of each group. 
The following observations are made from our study: 
 None of the cases of oral epithelial hyperplasia and oral epithelial dysplasia 
showed positivity for E6 oncoprotein of HPV16/18. Only four out of 15 cases 
of oral squamous cell carcinoma showed positive expression for E6 
oncoprotein HPV 16/18. 
 There was a statistically significant difference in immunopositivity for E6 
oncoprotein HPV 16/18 among the three different groups and a moderately 
strong association between the study groups and immunopositivity for E6 
oncoprotein HPV 16/18. 
 In the oral squamous cell carcinoma group, only two out of 6 cases of well 
differentiated squamous cell carcinoma, and two out of 8 cases of moderately 
differentiated squamous cell carcinoma were positive for E6 oncoprotein HPV 
16/18 
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 There was no significant difference in immunopositivity among different 
grades of oral squamous cell carcinoma statistically. Very weak association 
between the immunopositivity for E6 oncoprotein HPV 16/18 and grading of 
oral squamous cell carcinoma was detected. 
 All cases that were positive for E6 oncoprotein HPV 16/18 showed only mild 
staining intensity. Quantification showed that only 4% to 23% of cells had 
taken up the stain in these cases. 
 Koilocytosis was noticed in five cases of oral epithelial hyperplasia, two cases 
of oral epithelial dysplasia and five cases of oral squamous cell carcinoma. 
 There was no statistically significant difference in koilocytosis among the 
different study groups. 
 There was no significant difference in the presence of koilocytosis among 
different grades of oral squamous cell carcinoma. However, there was a 
moderately strong association between the presence of koilocytosis and 
grading of oral squamous cell carcinoma. 
 Although twelve out of 45 cases were positive for koilocytosis, none of these 
cases showed positive immunostaining for E6 oncoprotein HPV 16/18 
Based on the findings we can conclude that: 
E6 oncoprotein expression is noticed in few cases of oral squamous cell carcinoma. 
However, they are not expressed in cases of oral epithelial hyperplasia and oral 
epithelial dysplasia, suggesting that their role may be limited to a few but not all cases 
of oral squamous cell carcinoma. Since the prevalence of koilocytosis was noticed in 
more cases in all the groups, it is possible that a transient viral infection may be 
noticed in these oral lesions as a co infection. However, whether they play a direct 
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role in carcinogenesis in the oral cavity needs further assessment. It is also possible 
that the low prevalence of HPV in our study could be due to the component of the 
virus (i.e. E6 oncoprotein) chosen to be examined and its role in oral potential 
malignant disorders and oral squamous cell carcinoma needs to be established. 
Finally, it is possible that immunohistochemistry method is not sufficiently sensitive to 
identify HPV components in oral lesions. Studies in the same population using 
advance molecular methods like in situ hybridization or polymerase chain 
reactionmay be more beneficial to ascertain the role of HPV 16/18 in oral 
premalignant and malignant lesions. 
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Annexures
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1 
 E6 Positivity & Presence of Koilocytosis in Patients Belonging to Oral Epithelial Hyperplasia Group 
  
S. No 
Patient 
identification 
Age Sex Diagnosis Koilocytosis 
No of 
Koilocytes/HPF 
Positivity for 
E6 HPV 16/18 
Percentage of 
positive cells 
1. OEH 1 35 F Oral epithelial hyperplasia Yes 1 Negative 0% 
2. OEH 2 36 F Oral epithelial hyperplasia No 0 Negative 0% 
3. OEH 3 40 F Oral epithelial hyperplasia Yes 1 Negative 0% 
4. OEH 4 30 F Oral epithelial hyperplasia Yes 2 Negative 0% 
5. OEH 5 45 F Oral epithelial hyperplasia No 0 Negative 0% 
6. OEH 6 40 F Oral epithelial hyperplasia Yes 3 Negative 0% 
7. OEH 7 29 M Oral epithelial hyperplasia Yes 1 Negative 0% 
8. OEH 8 38 M Oral epithelial hyperplasia No 0 Negative 0% 
9. OEH 9 45 F Oral epithelial hyperplasia No 0 Negative 0% 
10. OEH10 45 F Oral epithelial hyperplasia No 0 Negative 0% 
11. OEH 11 57 M Oral epithelial hyperplasia No 0 Negative 0% 
12. OEH 12 82 M Oral epithelial hyperplasia No 0 Negative 0% 
13. OEH 13 49 M Oral epithelial hyperplasia No 0 Negative 0% 
14. OEH 14 40 M Oral epithelial hyperplasia No 0 Negative 0% 
15. OEH 15 40 M Oral epithelial hyperplasia No 0 Negative 0% 
  
8
2 
E6 Positivity & Presence of Koilocytosis in Patients Belonging to Oral Epithelial Dysplasia Group 
S. No 
Patient 
identification 
Age Sex Diagnosis Koilocytosis 
No of 
Koilocytes/HPF 
Positivity for E6 
HPV 16/18 
Percentage of 
positive cells 
1. OED 1 62 M Moderate dysplasia No 0 Negative 0% 
2. OED 2 65 M Severe dysplasia Yes 1 Negative 0% 
3. OED 3 51 M Moderate dysplasia No 0 Negative 0% 
4. OED 4 54 M Moderate dysplasia No 0 Negative 0% 
5. OED 5 54 F Moderate dysplasia No 0 Negative 0% 
6. OED 6 64 M Moderate dysplasia No 0 Negative 0% 
7. OED 7 44 M Moderate dysplasia No 0 Negative 0% 
8. OED 8 59 M Mild dysplasia Yes 2 Negative 0% 
9. OED 9 40 M Moderate dysplasia No 0 Negative 0% 
10. OED10 32 M Moderate dysplasia No 0 Negative 0% 
11. OED 11 55 M Mild dysplasia No 0 Negative 0% 
12. OED 12 40 M Mild dysplasia No 0 Negative 0% 
13. OED 13 66 M Mild dysplasia No 0 Negative 0% 
14. OED 14 65 F Moderatedysplasia No 0 Negative 0% 
15. OED 15 57 M Moderatedysplasia No 0 Negative 0% 
 
  
  
8
3 
E6 Positivity & Presence of Koilocytosis in Patients Belonging to Oral Squamous Cell Carcinoma Group 
S. No 
Patient 
identification 
Age Sex Diagnosis Koilocytosis 
No of 
Koilocytes/HPF 
Positivity for E6 
HPV 16/18 
Percentage of 
positive cells 
1. OSCC 1 57 M Poorly differentiated Yes 3 Negative 0% 
2. OSCC 2 38 M Moderately differentiated No 0 Negative 0% 
3. OSCC 3 65 M Moderately differentiated No 0 Negative 0% 
4. OSCC 4 80 M Moderately differentiated Yes 1 Negative 0% 
5. OSCC 5 50 M Well differentiated No 0 Positive 23% 
6. OSCC 6 54 M Well differentiated No 0 Negative 0% 
7. OSCC 7 61 M Moderately differentiated No 0 Positive 18% 
8. OSCC 8 60 M Well differentiated No 0 Negative 0% 
9. OSCC 9 45 F Well differentiated No 0 Negative 0% 
10. OSCC 10 54 M Moderately differentiated No 0 Positive 4% 
11. OSCC 11 58 F Moderately differentiated Yes 1 Negative 0% 
12. OSCC 12 60 M Moderately differentiated No 0 Negative 0% 
13. OSCC 13 61 M Well differentiated Yes 1 Negative 0% 
14. OSCC 14 70 M Well differentiated No 0 Positive 4% 
15. OSCC 15 80 F Moderately differentiated Yes 1 Negative 0% 
 
